AstraZeneca Defends Crestor Again; Circulation Publishes Safety Analysis
A medical journal article suggesting a higher risk of muscle and kidney toxicity associated with Crestor compared to other statins is misleading and in "direct contrast" to FDA's position, AstraZeneca said May 23
You may also be interested in...
FDA says AstraZeneca's Crestor is as safe as, if not safer than, other statins for a given LDL-lowering efficacy, but its ad campaign cannot claim superiority to Pfizer's Lipitor
FDA's focus following the Senate Finance Committee hearing on the Vioxx withdrawal is on defending the safety of five other drugs challenged by one of its safety reviewers
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011